Global Angioedema Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034

The global angioedema treatment market size is expected to reach USD 3.92 Billion in 2034 from USD 1.63 Billion in 2025, growing at a CAGR of 10.23% during 2026-2034.This market is gaining importance as healthcare professionals seek effective approaches to managing angioedema, a condition characterized by swelling beneath the skin or in mucosal tissues. Angioedema may be associated with allergic reactions, certain medications, or hereditary conditions involving abnormalities in inflammatory pathways. Growing awareness of the condition, improved diagnostic capabilities, and increasing recognition of hereditary angioedema are supporting demand for appropriate treatments. Because some episodes can involve the airway and become life-threatening, timely recognition and access to suitable medical care remain essential. These factors are encouraging continued attention to treatment availability and disease management.

Market growth is supported by advances in targeted therapies, improved understanding of disease mechanisms, and increasing availability of specialized treatment options. Treatments vary according to the underlying cause and may include emergency medications for allergic reactions, therapies targeting bradykinin pathways in hereditary angioedema, and preventive treatments for eligible patients. Pharmaceutical companies are investing in research aimed at reducing attack frequency and improving disease control. Greater access to specialist care, patient education programs, and improved diagnostic testing are also supporting treatment adoption. In addition, the development of more convenient administration methods is helping address patient preferences and treatment-management requirements.

The future prospects of this market will be influenced by advances in targeted treatment, preventive therapies, and improved approaches to identifying patients at risk of recurrent episodes. Research into novel biological pathways may create opportunities for therapies with improved effectiveness and dosing convenience. Better diagnostic awareness could also reduce delays in identifying hereditary and medication-related forms of angioedema. However, treatment affordability, differences in healthcare access, and the need for rapid intervention during severe episodes remain important considerations. Continued clinical research, patient education, and improvements in emergency preparedness are expected to support further development of the treatment landscape.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Condition Type

• Allergic Angioedema
• Drug-Induced Angioedema
• Idiopathic Angioedema
• Hereditary Angioedema (HAE)

By Drug Type

• C1 Esterase Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Others

By Route of Administration

• Injection
• Oral

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Takeda, CSL, BioCryst Pharmaceuticals, Pharming Group, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharvaris, Intellia Therapeutics, Astria Therapeutics, Adverum Biotechnologies, Arrowhead Pharmaceuticals, Sanofi, Attune Pharmaceuticals, ADARx Pharmaceuticals, Regeneron Pharmaceuticals, Otsuka Pharmaceutical, Grifols, Sobi, Octapharma, Kedrion Biopharma